Pharmafile Logo
Pharmafocus logo
Advanced Search

osteoporosis

Showing 15 posts of 21 posts found.

Rani Therapeutics’ oral ‘robotic pill’ delivers injection trans-enterically

June 19, 2023
Medical Communications Osteoporosis, Rani Therapeutics, injection, osteoporosis, robotic pill, robotics

US Rani Therapeutics, a clinical-stage biotherapeutics company, has reported new results from its phase 1 trial into the RaniPill capsule …

News

Theramex releases Vitamin D gel aimed at women

May 5, 2021
Research and Development Theramex, osteoporosis, pharma, pharma news, vitamin d

Theramex has launched a new gel for Vitamin D deficiency, in the hope that it will particularly treat women experiencing …

News
senior-woman-suffering-from-knee-pain-home_61573-2004

Theramex launches osteoporosis drug Livogiva in Europe

January 18, 2021
Sales and Marketing Theramex, osteoporosis

Theramex, a London-headquartered pharmaceutical company dedicated to women’s health, has launched osteoporosis medicine Livogiva to patients in Europe for the …

News

FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture

October 9, 2019
Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma

The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …

News
fdaoutsideweb

FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients

April 10, 2019
Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma

The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …

News
x_ray_health_arm_doctors_medicine_bone_hospital_medical_insurance-480473

Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds

April 8, 2019
Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data

A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …

News
bonecells

Amgen and UCB’s Evenity approved in Japan for osteoporosis

January 9, 2019
Research and Development, Sales and Marketing Amgen, Japan, UCB Pharma, osteoporosis, pharma

Amgen has revealed that its bone-forming monoclonal antibody Evenity (romosozumab), developed in partnership with UCB Pharma, has been awarded approval …

News

FDA refuses approval of Amgen osteoporosis drug

July 17, 2017
Sales and Marketing Amgen, Evenity, Radial, UCB, biotech, drugs, osteoporosis, pharma, pharmaceutical

Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …

News
x-ray-1704854_960_720

Osteoporosis drugs potentially causing long-term bone weakness

March 2, 2017
Research and Development osteoporosis

Medication that is used to treat those suffering from weakened bones may actually be causing further damage, new research from …

News
merck_and_co

MSD drops osteoporosis trial drug due to stroke risk

September 5, 2016
Research and Development, Sales and Marketing MSD, Merck, Odanacatib, osteoporosis, stroke

MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development …

News
tablet_production_2

Further positive trial results boost Amgen and UCB’s romosozumab

March 21, 2016
Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval

Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …

News
ucb_logo_and_chief_executive

UCB targets regulatory filing for its osteoporosis drug in 2016

March 3, 2016
Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis

Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …

News
amgen_ucb

Amgen and UCB announce positive romosozumab results

February 22, 2016
Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis

Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …

News
Amgen image

Amgen files high earnings for Q1

April 22, 2015
Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis

Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …

News

UCB and Amgen’s osteoporosis drug shows promise

April 21, 2011
Research and Development Amgen, UCB, osteoporosis

Amgen and UCB have announced strong results from a phase II study of their new postmenopausal osteoporosis treatment. Most existing …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023